IBDEI10N ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16523,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,16523,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,16524,0)
 ;;=D68.32^^61^775^89
 ;;^UTILITY(U,$J,358.3,16524,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16524,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,16524,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,16524,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,16525,0)
 ;;=C22.2^^61^775^90
 ;;^UTILITY(U,$J,358.3,16525,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16525,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,16525,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,16525,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,16526,0)
 ;;=D58.9^^61^775^92
 ;;^UTILITY(U,$J,358.3,16526,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16526,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,16526,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,16526,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,16527,0)
 ;;=C81.99^^61^775^93
 ;;^UTILITY(U,$J,358.3,16527,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16527,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,16527,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,16527,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,16528,0)
 ;;=C81.90^^61^775^94
 ;;^UTILITY(U,$J,358.3,16528,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16528,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,16528,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,16528,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,16529,0)
 ;;=D89.2^^61^775^95
 ;;^UTILITY(U,$J,358.3,16529,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16529,1,3,0)
 ;;=3^Hypergammaglobulenemia,Unspec
 ;;^UTILITY(U,$J,358.3,16529,1,4,0)
 ;;=4^D89.2
 ;;^UTILITY(U,$J,358.3,16529,2)
 ;;=^5002455
 ;;^UTILITY(U,$J,358.3,16530,0)
 ;;=D05.12^^61^775^98
 ;;^UTILITY(U,$J,358.3,16530,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16530,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,16530,1,4,0)
 ;;=4^D05.12
 ;;^UTILITY(U,$J,358.3,16530,2)
 ;;=^5001931
 ;;^UTILITY(U,$J,358.3,16531,0)
 ;;=D05.11^^61^775^99
 ;;^UTILITY(U,$J,358.3,16531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16531,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,16531,1,4,0)
 ;;=4^D05.11
 ;;^UTILITY(U,$J,358.3,16531,2)
 ;;=^5001930
 ;;^UTILITY(U,$J,358.3,16532,0)
 ;;=D05.10^^61^775^100
 ;;^UTILITY(U,$J,358.3,16532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16532,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,16532,1,4,0)
 ;;=4^D05.10
 ;;^UTILITY(U,$J,358.3,16532,2)
 ;;=^5001929
 ;;^UTILITY(U,$J,358.3,16533,0)
 ;;=D50.0^^61^775^101
 ;;^UTILITY(U,$J,358.3,16533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16533,1,3,0)
 ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
 ;;^UTILITY(U,$J,358.3,16533,1,4,0)
 ;;=4^D50.0
 ;;^UTILITY(U,$J,358.3,16533,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,16534,0)
 ;;=D50.9^^61^775^102
 ;;^UTILITY(U,$J,358.3,16534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16534,1,3,0)
 ;;=3^Iron Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,16534,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,16534,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,16535,0)
 ;;=C46.9^^61^775^103
 ;;^UTILITY(U,$J,358.3,16535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16535,1,3,0)
 ;;=3^Kaposi's Sarcoma,Unspec
 ;;^UTILITY(U,$J,358.3,16535,1,4,0)
 ;;=4^C46.9
